Cadmium chloride: Carcinogenic Potency Database

Cadmium chloride (CAS 10108-64-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
hmo kid lun pro tes	lun	no test	no positive	0.0136^m,v	no positive

Hamsters: Cancer Test Summary

Hamster Target Sites		TD₅₀ (mg/kg/day)
Male	Female	TD₅₀ (mg/kg/day)
no positive	no positive	no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: hmo = hematopoietic system. kid = kidney. lun = lung. pro = prostate. tes = testes. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD₅₀ values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Cadmium chloride: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



CADMIUM CHLORIDE   10108-64-2
996  H f syg inh 60w76 1909m                         0    52.5ug                            Heinrich;expl,37,253-258;1989/pers.comm.
 lun tum or     no dre   P=1.    -  .139mg n.s.s.   0/24    0/24
997  H f syg inh 64w76 1909n                         0    18.7ug
 lun tum or     no dre   P=1.    -  49.3ug n.s.s.   0/24    0/24
998  H m syg inh 14m24 1909m                         0    34.5ug
 lun tum or     no dre   P=1.    -  .164mg n.s.s.   0/24    0/24
999  H m syg inh 15m26 1909n                         0    11.1ug
 lun tum or     no dre   P=1.    -  64.6ug n.s.s.   0/24    0/24
1000 M f nmr inh 42w82 1909m                         0    75.0ug
 lun mix eor    no dre   P=1.    -  .126mg n.s.s.  11/43    8/41
 lun ade eor    no dre   P=1.    -  .139mg n.s.s.   8/43    6/41
 lun adc eor    no dre   P=1.    -  .211mg n.s.s.   3/43    2/41
1001 M f nmr inh 69w89 1909n                         0    37.8ug
 lun ade eor    no dre   P=1.    -  .207mg n.s.s.   9/45    1/43
 lun mix eor    no dre   P=1.    -  .221mg n.s.s.  17/45    1/43
 lun adc eor    no dre   P=1.    -  .246mg n.s.s.   8/45    0/43
1002 R m nbl wat 24m24 2599                          0    2.04mg  4.07mg  8.15mg  16.3mg     Waalkes;jtxe,58,199-214;1999/pers.comm.
 kid mix e      114.mg * P<.008  +  43.1mg 2.34gm   0/29    0/29    0/29    2/30    3/29
 kid mmt e      193.mg * P<.08      58.4mg n.s.s.   0/29    0/29    0/29    2/30    1/29
 k/p tcc e      584.mg * P<.2       95.1mg n.s.s.   0/29    0/29    0/29    0/30    1/29
 kid lip e      584.mg * P<.2       95.1mg n.s.s.   0/29    0/29    0/29    0/30    1/29
 adr pbm e      686.mg * P<.9       28.4mg n.s.s.   2/29    3/30    8/30    6/30    3/29
 liv tum e      no dre   P=1.       6.33mg n.s.s.   0/29    0/29    0/30    0/30    0/29
 pro tum e      no dre   P=1.       5.69mg n.s.s.   0/28    0/26    0/26    0/29    0/27
1003 R f wis inh  6m29 1908m                         0    11.7ug                            Oldiges;txec,19,217-222;1989/Glaser 1990
 lun mix eor    64.5ug   P<.03      19.5ug n.s.s.   0/20    3/18
 lun sqa eor    99.8ug   P<.08      24.5ug n.s.s.   0/20    2/18
 lun adc eor    .206mg   P<.3       33.5ug n.s.s.   0/20    1/18
1004 R f wis inh 18m31 1908n                         0    10.9ug
 lun mix eor    9.71ug   P<.0005 +  4.81ug 22.7ug   0/20   13/18
 lun adc eor    25.3ug   P<.0005    10.8ug 88.9ug   0/20    7/18
 lun a/a eor    49.5ug   P<.02      17.0ug n.s.s.   0/20    4/18
 lun adq eor    .106mg   P<.08      25.9ug n.s.s.   0/20    2/18
1005 R m wis inh 18m31 1907                          0    3.34ug  6.68ug  13.4ug                       Takenaka;jnci,70,367-373;1983
 lun car eo     12.7ug * P<.0005 +  8.89ug 18.8ug   0/38    6/39   20/38   25/35
 lun adc eo     22.0ug * P<.0005    14.6ug 35.9ug   0/38    4/39   16/38   15/35
 lun epc eo     58.8ug * P<.0005    32.3ug .158mg   0/38    2/39    5/38    8/35
 lun mec eo     .315mg * P<.03      95.5ug n.s.s.   0/38    0/39    0/38    3/35
 lun ade eo     .563mg * P<.5       .118mg n.s.s.   0/38    1/39    0/38    1/35
 adr pbm eo     .591mg * P<.8       49.7ug n.s.s.   2/38    8/39    4/38    4/35
1006 R m wis inh  6m30 1908m                         0    7.91ug                            Oldiges;txec,19,217-222;1989/Glaser 1990
 lun mix eor    10.6ug   P<.0005 +  5.19ug 26.3ug   0/40   11/20
 lun adc eor    29.4ug   P<.002     11.1ug .128mg   0/40    5/20
 lun a/a eor    52.1ug   P<.01      15.7ug 2.57mg   0/40    3/20
 lun sqa eor    52.1ug   P<.01      15.7ug 2.57mg   0/40    3/20
1007 R m wis inh 18m30 1908n                         0    7.91ug
 lun mix eor    6.11ug   P<.0005 +  3.13ug 13.5ug   0/40   15/20
 lun adc eor    9.24ug   P<.0005    4.61ug 22.1ug   0/40   12/20
 lun a/a eor    80.4ug   P<.04      19.8ug n.s.s.   0/40    2/20
 lun adq eor    .165mg   P<.2       26.9ug n.s.s.   0/40    1/20
1008 R m wis eat 77w77 2027                          0    1.63mg  3.26mg  6.52mg  13.0mg     Waalkes;faat,19,512-520;1992/pers.comm.
 tes icb e      31.6mg * P<.03   +  12.1mg n.s.s.   1/28    2/27    1/25    1/24    6/27
 pro ade e      56.9mg * P<.3    +  15.3mg n.s.s.   0/28    1/26    2/22    1/23    2/26
 --- lle e      no dre   P=1.    +  16.9mg n.s.s.   1/28    4/27    5/24    5/24    1/27
1009 R m wis wat 78w78 2658                          0    4.00mg                                           Martin;prst,46,11-20;2001
 prv tum Cer    no dre   P=1.       4.64mg n.s.s.   0/10    0/10

Mutagenicity in Salmonella: negative
SMILES Code for Cadmium chloride: [Cl-].[Cd+2].[Cl-]
InChI Code for Cadmium chloride: InChI=1/Cd.2ClH/h;2*1H/q+2;;/p-2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for Cadmium chloride:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007